BridgeBio Pharma Inc vs Otis Worldwide Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Otis Worldwide Corp trades at $73.25 (market cap $27.80B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.41% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | OTIS | |
|---|---|---|
Market Cap | $16.36B | $27.80B |
Sector | Health | Industrials |
52-Week High | $90.17 | $93.62 |
52-Week Low | $47.29 | $69.34 |
Enterprise Value | $18.14B | $35.84B |
Dividend Yield | — | 2.41% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →